OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like g...OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.展开更多
目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD...目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。展开更多
目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体...目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体重儿的初产妇66例,分为妊娠16～18周、妊娠26～28周、妊娠37～40周3个阶段进行纵向观察,放射免疫法测定孕妇各阶段血清中IGF-1、IGF-2、IGFBP-3水平并进行对比分析。结果孕期母血IGF-1水平随着孕周增加明显上升,其中IGF-1水平在妊娠37～40周高于妊娠26～28周,妊娠26～28周高于妊娠16～18周,差异均有显著统计学意义(P均<0.01)。孕期母血IGF-2水平随孕周增加无明显改变,妊娠3阶段差异无统计学意义(P>0.05)。母血IGFBP-3水平妊娠37～40周高于妊娠26～28周及妊娠16～18周期,差异有统计学意义(P<0.05),而妊娠26～28周与妊娠16～18周无显著差异。妊娠16～18周、26～28周和37～40周3阶段母血IGF-1、IGF-2、IGFBP-3水平与正常新生儿出生体重无显著相关性。结论孕妇血清IGF-1、IGFBP-3水平与正常胎儿生长密切相关,IGF-1可作为临床评价不同阶段正常胎儿生长的指标,而IGFBP-3更多地反映了妊娠中晚期正常胎儿的生长。展开更多
目的观察IGF-1、IGFBP-3、TNF-α在绝经后2型糖尿病(type 2 diabetes,T2DM)骨质疏松症(osteoporosis,OP)患者中的表达特点,以及经抗骨质疏松治疗前后骨密度(bone mineral density,BMD)、骨代谢的变化,探讨IGF-1、IGFBP-3、TNF-α作为OP...目的观察IGF-1、IGFBP-3、TNF-α在绝经后2型糖尿病(type 2 diabetes,T2DM)骨质疏松症(osteoporosis,OP)患者中的表达特点,以及经抗骨质疏松治疗前后骨密度(bone mineral density,BMD)、骨代谢的变化,探讨IGF-1、IGFBP-3、TNF-α作为OP疗效评判指标的可行性。方法选取2018年5月至2020年6月在上海市中医药大学附属普陀区中心医院就诊的T2DM合并绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)患者共95例,失访7例,最终纳入88例,化验治疗前及治疗1年后的IGF-1、IGFBP-3、TNF-α,并测量BMD。结果(1)IGF-1、IGFBP-3在抗骨质疏松药物治疗后水平均较前升高;而TNF-α则表达减少(P<0.05);(2)治疗后全髋、股骨颈及腰1~4的BMD以及IGF-1、IGFBP-3较治疗前有上升,TNF-α下降,Ward’s三角、大粗隆、股骨干的BMD变化不大;(3)治疗后β-CTX降低(P<0.05),TP1NP、25(OH)D升高(P<0.05),PTH和OC无明显变化;(4)治疗后,将各部位BMD与IGF-1、IGFBP-3、TNF-α等化验数据作相关性分析,提示股骨颈BMD与IGF-1、IGFBP-3存在正相关,腰1~4的BMD与TNF-α存在负相关,差异有统计学意义(P<0.05);(5)25(OH)D及TP1NP均与IGF-1、IGFBP-3存在正相关,与TNF-α负相关;β-CTX与TNF-α存在正相关,与IGFBP-3负相关,差异有统计学意义(P<0.05)。结论IGF-1、IGFBP-3、TNF-α与BMD、骨代谢的变化有一定关系,骨质疏松治疗后患者的骨形成指标TP1NP增加、25(OH)D增加,骨吸收指标β-CTX减少,同步发生变化的还有骨密度的有效提高,以及IGF-1、IGFBP-3的增加和TNF-α的降低。通过对IGF-1、IGFBP-3、TNF-α检测联合骨代谢指标的改善可以有效评估骨质疏松的治疗效果。展开更多
基金supported by National Natural Science Foundation of China(81502123 and81330081)Natural Science Foundation of Anhui Province(1308085QH130)Anhui Province Nature Science Foundation in University(KJ2014A119)
文摘OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.
文摘目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。
文摘目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体重儿的初产妇66例,分为妊娠16～18周、妊娠26～28周、妊娠37～40周3个阶段进行纵向观察,放射免疫法测定孕妇各阶段血清中IGF-1、IGF-2、IGFBP-3水平并进行对比分析。结果孕期母血IGF-1水平随着孕周增加明显上升,其中IGF-1水平在妊娠37～40周高于妊娠26～28周,妊娠26～28周高于妊娠16～18周,差异均有显著统计学意义(P均<0.01)。孕期母血IGF-2水平随孕周增加无明显改变,妊娠3阶段差异无统计学意义(P>0.05)。母血IGFBP-3水平妊娠37～40周高于妊娠26～28周及妊娠16～18周期,差异有统计学意义(P<0.05),而妊娠26～28周与妊娠16～18周无显著差异。妊娠16～18周、26～28周和37～40周3阶段母血IGF-1、IGF-2、IGFBP-3水平与正常新生儿出生体重无显著相关性。结论孕妇血清IGF-1、IGFBP-3水平与正常胎儿生长密切相关,IGF-1可作为临床评价不同阶段正常胎儿生长的指标,而IGFBP-3更多地反映了妊娠中晚期正常胎儿的生长。
